DURHAM – Velocity Clinical Research continues to grow its US network, adding two more sites this week following its recent acquisition by GHO Capital three months ago. Next stop: Europe.
Adding New York-based Clarity Clinical Research and California-based Providence Clinical Research, Velocity has grown to 18 sites across 12 states since launching in late 2017.
And the firm says it is not slowing down, noting it “looks to expand” to Europe in coming months.
“The capital from our new owners, GHO, has meant Velocity can keep expanding its integrated network of sites at an aggressive pace,” said G. Paul Evans, Velocity’s CEO. “Despite working on our own deal that was only completed in April this year, it has not slowed down our commitment to addressing an incredibly fragmented clinical trial site landscape in the U.S. by creating a fully integrated network. Adding Clarity Clinical Research and Providence Clinical Research to the Velocity network is testament to that.”
